Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alza in-line I.V. system

Executive Summary

The first Baxter product using the system will not be for "post-surgical pain," as reported in "The Pink Sheet" Oct. 29 (p. 16). Baxter has filed an ANDA but has not disclosed what drug is involved. In addition, the "one-time deduction" for the start-up of Alza's new Vacaville, Calif. manufacturing facility is the initial of two or three quarterly deductions of approximately the same amount. Alza retains an option to acquire Bio-Electro Systems until its stockholder's equity drop below $4 mil., not $6 mil. as was reported....Bristol-Myers Squibb's Pravachol: HMG-CoA reductase inhibitor pravastatin was studied at 40 mg QD (once a day) and 20 mg b.i.d., not four times a day ("The Pink Sheet", Oct. 29, p. 8).

The first Baxter product using the system will not be for "post-surgical pain," as reported in "The Pink Sheet" Oct. 29 (p. 16). Baxter has filed an ANDA but has not disclosed what drug is involved. In addition, the "one-time deduction" for the start-up of Alza's new Vacaville, Calif. manufacturing facility is the initial of two or three quarterly deductions of approximately the same amount. Alza retains an option to acquire Bio-Electro Systems until its stockholder's equity drop below $4 mil., not $6 mil. as was reported....Bristol-Myers Squibb's Pravachol: HMG-CoA reductase inhibitor pravastatin was studied at 40 mg QD (once a day) and 20 mg b.i.d., not four times a day ("The Pink Sheet", Oct. 29, p. 8).

Latest Headlines
See All
UsernamePublicRestriction

Register

PS018341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel